- Home
- AVIR vs SLS Comparison
AVIR vs SLS Comparison
Compare AVIR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- SLS
- Stock Information
- Founded
- AVIR 2012
- SLS 2012
- Country
- AVIR United States
- SLS United States
- Employees
- AVIR N/A
- SLS N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- SLS Health Care
- Exchange
- AVIR Nasdaq
- SLS Nasdaq
- Market Cap
- AVIR 290.4M
- SLS 238.7M
- IPO Year
- AVIR 2020
- SLS N/A
- Fundamental
- Price
- AVIR $3.27
- SLS $1.90
- Analyst Decision
- AVIR Hold
- SLS Strong Buy
- Analyst Count
- AVIR 1
- SLS 1
- Target Price
- AVIR $6.00
- SLS $7.00
- AVG Volume (30 Days)
- AVIR 453.6K
- SLS 5.1M
- Earning Date
- AVIR 11-07-2025
- SLS 11-07-2025
- Dividend Yield
- AVIR N/A
- SLS N/A
- EPS Growth
- AVIR N/A
- SLS N/A
- EPS
- AVIR N/A
- SLS N/A
- Revenue
- AVIR N/A
- SLS N/A
- Revenue This Year
- AVIR N/A
- SLS N/A
- Revenue Next Year
- AVIR N/A
- SLS N/A
- P/E Ratio
- AVIR N/A
- SLS N/A
- Revenue Growth
- AVIR N/A
- SLS N/A
- 52 Week Low
- AVIR $2.46
- SLS $0.77
- 52 Week High
- AVIR $4.02
- SLS $2.48
- Technical
- Relative Strength Index (RSI)
- AVIR 57.88
- SLS 48.86
- Support Level
- AVIR $3.15
- SLS $1.85
- Resistance Level
- AVIR $3.34
- SLS $2.06
- Average True Range (ATR)
- AVIR 0.10
- SLS 0.18
- MACD
- AVIR 0.02
- SLS -0.02
- Stochastic Oscillator
- AVIR 79.37
- SLS 7.94
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.